Catalent Inc (NASDAQ:CTLT) – Research analysts at KeyCorp upped their FY2017 earnings per share estimates for Catalent in a note issued to investors on Monday. KeyCorp analyst M. Mishan now forecasts that the company will post earnings of $1.27 per share for the year, up from their previous estimate of $1.26. KeyCorp also issued estimates for Catalent’s Q4 2017 earnings at $0.55 EPS, FY2018 earnings at $1.49 EPS and FY2019 earnings at $1.70 EPS.
Catalent (NASDAQ:CTLT) last posted its earnings results on Thursday, May 4th. The company reported $0.38 EPS for the quarter, beating the consensus estimate of $0.36 by $0.02. The firm had revenue of $532.60 million during the quarter, compared to the consensus estimate of $470.95 million. Catalent had a return on equity of 16.95% and a net margin of 4.88%. The business’s quarterly revenue was up 21.6% on a year-over-year basis. During the same period last year, the company earned $0.21 earnings per share.
COPYRIGHT VIOLATION NOTICE: This article was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/08/07/equities-analysts-offer-predictions-for-catalent-incs-fy2017-earnings-nasdaqctlt-updated-updated-updated.html.
A number of other equities research analysts have also weighed in on the company. Zacks Investment Research raised Catalent from a “sell” rating to a “buy” rating and set a $39.00 target price for the company in a research note on Tuesday, July 4th. BidaskClub lowered Catalent from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 27th. Bank of America Corporation reaffirmed a “buy” rating and set a $37.00 price target (up previously from $32.00) on shares of Catalent in a research report on Wednesday, May 17th. William Blair raised Catalent from a “market perform” rating to an “outperform” rating in a research report on Monday, May 15th. Finally, TheStreet raised Catalent from a “c” rating to a “b-” rating in a research report on Wednesday, April 19th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Catalent presently has a consensus rating of “Buy” and an average target price of $31.86.
Catalent (NASDAQ:CTLT) traded down 1.88% during trading on Wednesday, reaching $35.58. The company’s stock had a trading volume of 215,172 shares. The company has a market cap of $4.45 billion and a PE ratio of 41.91. Catalent has a 52-week low of $21.83 and a 52-week high of $38.73. The stock has a 50-day moving average price of $35.84 and a 200 day moving average price of $30.01.
In related news, insider Sharon Johnson sold 9,160 shares of the company’s stock in a transaction that occurred on Tuesday, April 25th. The stock was sold at an average price of $29.00, for a total value of $265,640.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
A number of institutional investors have recently added to or reduced their stakes in CTLT. Acadian Asset Management LLC boosted its position in Catalent by 115.7% in the first quarter. Acadian Asset Management LLC now owns 5,847 shares of the company’s stock valued at $166,000 after buying an additional 3,136 shares during the period. Nationwide Fund Advisors boosted its position in Catalent by 8.0% in the first quarter. Nationwide Fund Advisors now owns 291,103 shares of the company’s stock valued at $8,244,000 after buying an additional 21,540 shares during the period. Louisiana State Employees Retirement System boosted its position in Catalent by 2.3% in the first quarter. Louisiana State Employees Retirement System now owns 31,500 shares of the company’s stock valued at $892,000 after buying an additional 700 shares during the period. CWM LLC acquired a new position in Catalent during the first quarter valued at about $2,508,000. Finally, Fox Run Management L.L.C. acquired a new position in Catalent during the first quarter valued at about $346,000.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Stock Ratings for Catalent Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Catalent Inc and related stocks with our FREE daily email newsletter.